Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
Identifieur interne : 000281 ( France/Analysis ); précédent : 000280; suivant : 000282Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
Auteurs : Sara Murias [France] ; Lorena Magallares ; Fatima Albizuri ; Dora Pascual-Salcedo ; Erwin Dreesen ; Denis MullemanSource :
- Therapeutic drug monitoring [ 1536-3694 ] ; 2017.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (sang), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (sang), Antirhumatismaux (usage thérapeutique), Biopharmacie (), Enfant, Humains, Maladies inflammatoires intestinales (sang), Maladies inflammatoires intestinales (traitement médicamenteux), Polyarthrite rhumatoïde (sang), Polyarthrite rhumatoïde (traitement médicamenteux), Produits biologiques (sang), Produits biologiques (usage thérapeutique), Psoriasis (sang), Psoriasis (traitement médicamenteux), Pédiatrie (), Surveillance pharmacologique ().
- MESH :
- sang : Anticorps monoclonaux humanisés, Antirhumatismaux, Maladies inflammatoires intestinales, Polyarthrite rhumatoïde, Produits biologiques, Psoriasis.
- traitement médicamenteux : Maladies inflammatoires intestinales, Polyarthrite rhumatoïde, Psoriasis.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques.
- Biopharmacie, Enfant, Humains, Pédiatrie, Surveillance pharmacologique.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (blood), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (blood), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (blood), Arthritis, Rheumatoid (drug therapy), Biological Products (blood), Biological Products (therapeutic use), Biopharmaceutics (methods), Child, Drug Monitoring (methods), Humans, Inflammatory Bowel Diseases (blood), Inflammatory Bowel Diseases (drug therapy), Pediatrics (methods), Psoriasis (blood), Psoriasis (drug therapy).
- MESH :
- chemical , blood : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products.
- blood : Arthritis, Rheumatoid, Inflammatory Bowel Diseases, Psoriasis.
- drug therapy : Arthritis, Rheumatoid, Inflammatory Bowel Diseases, Psoriasis.
- methods : Biopharmaceutics, Drug Monitoring, Pediatrics.
- Child, Humans.
Abstract
Biopharmaceuticals have recently emerged as effective treatments for refractory pediatric autoimmune conditions. Several reports have shown a relationship between drug concentration, antidrug antibodies, and clinical response in these patients, strongly suggesting the potential interest, usefulness, and reliability of therapeutic drug monitoring (TDM) in children. This article reviews the current state of research in juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric psoriasis from a TDM point of view. There is a remarkable lack of evidence-based data in pediatric patients, which is reflected throughout the article. Most investigations of TDM are focused on research of tumor necrosis factor alpha antagonists in inflammatory bowel disease, albeit preliminary publications are emerging from pediatric rheumatologists and dermatologists. To date, immunogenicity has been a primary concern, particularly regarding infliximab and adalimumab therapy in children, as it may lead to a loss of therapeutic response. Preliminary investigations show that adjusting the dose according to blood drug concentrations improves disease outcomes by overcoming antidrug antibodies, suggesting a crucial role for TDM. Patients who receive other drugs, such as etanercept, abatacept, or tocilizumab, could benefit from TDM because dosage can be optimized by adjusting it to the minimum effective dose.
Url:
DOI: 10.1097/FTD.0000000000000423
PubMed: 28703718
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A86
- to stream PubMed, to step Curation: 000A86
- to stream PubMed, to step Checkpoint: 000B88
- to stream Ncbi, to step Merge: 001657
- to stream Ncbi, to step Curation: 001657
- to stream Ncbi, to step Checkpoint: 001657
- to stream Hal, to step Corpus: 000019
- to stream Hal, to step Curation: 000019
- to stream Hal, to step Checkpoint: 000049
- to stream Main, to step Merge: 001853
- to stream Main, to step Curation: 001854
- to stream Main, to step Exploration: 001854
- to stream France, to step Extraction: 000281
Links to Exploration step
pubmed:28703718Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.</title><author><name sortKey="Murias, Sara" sort="Murias, Sara" uniqKey="Murias S" first="Sara" last="Murias">Sara Murias</name><affiliation wicri:level="3"><nlm:affiliation>Departments of *Pediatric Rheumatology,†Pediatric Gastroenterology,‡Pediatric Dermatology, and§Immunology, University Hospital La Paz, Madrid, Spain;¶Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and‖Department of Rheumatology, Université François-Rabelais de Tours, Tours, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of *Pediatric Rheumatology,†Pediatric Gastroenterology,‡Pediatric Dermatology, and§Immunology, University Hospital La Paz, Madrid, Spain;¶Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and‖Department of Rheumatology, Université François-Rabelais de Tours, Tours</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Magallares, Lorena" sort="Magallares, Lorena" uniqKey="Magallares L" first="Lorena" last="Magallares">Lorena Magallares</name></author><author><name sortKey="Albizuri, Fatima" sort="Albizuri, Fatima" uniqKey="Albizuri F" first="Fatima" last="Albizuri">Fatima Albizuri</name></author><author><name sortKey="Pascual Salcedo, Dora" sort="Pascual Salcedo, Dora" uniqKey="Pascual Salcedo D" first="Dora" last="Pascual-Salcedo">Dora Pascual-Salcedo</name></author><author><name sortKey="Dreesen, Erwin" sort="Dreesen, Erwin" uniqKey="Dreesen E" first="Erwin" last="Dreesen">Erwin Dreesen</name></author><author><name sortKey="Mulleman, Denis" sort="Mulleman, Denis" uniqKey="Mulleman D" first="Denis" last="Mulleman">Denis Mulleman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28703718</idno><idno type="pmid">28703718</idno><idno type="doi">10.1097/FTD.0000000000000423</idno><idno type="wicri:Area/PubMed/Corpus">000A86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A86</idno><idno type="wicri:Area/PubMed/Curation">000A86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A86</idno><idno type="wicri:Area/PubMed/Checkpoint">000B88</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B88</idno><idno type="wicri:Area/Ncbi/Merge">001657</idno><idno type="wicri:Area/Ncbi/Curation">001657</idno><idno type="wicri:Area/Ncbi/Checkpoint">001657</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01980767</idno><idno type="url">https://hal-univ-tours.archives-ouvertes.fr/hal-01980767</idno><idno type="wicri:Area/Hal/Corpus">000019</idno><idno type="wicri:Area/Hal/Curation">000019</idno><idno type="wicri:Area/Hal/Checkpoint">000049</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000049</idno><idno type="wicri:doubleKey">0163-4356:2017:Murias S:current:practices:for</idno><idno type="wicri:Area/Main/Merge">001853</idno><idno type="wicri:Area/Main/Curation">001854</idno><idno type="wicri:Area/Main/Exploration">001854</idno><idno type="wicri:Area/France/Extraction">000281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.</title><author><name sortKey="Murias, Sara" sort="Murias, Sara" uniqKey="Murias S" first="Sara" last="Murias">Sara Murias</name><affiliation wicri:level="3"><nlm:affiliation>Departments of *Pediatric Rheumatology,†Pediatric Gastroenterology,‡Pediatric Dermatology, and§Immunology, University Hospital La Paz, Madrid, Spain;¶Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and‖Department of Rheumatology, Université François-Rabelais de Tours, Tours, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of *Pediatric Rheumatology,†Pediatric Gastroenterology,‡Pediatric Dermatology, and§Immunology, University Hospital La Paz, Madrid, Spain;¶Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and‖Department of Rheumatology, Université François-Rabelais de Tours, Tours</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Magallares, Lorena" sort="Magallares, Lorena" uniqKey="Magallares L" first="Lorena" last="Magallares">Lorena Magallares</name></author><author><name sortKey="Albizuri, Fatima" sort="Albizuri, Fatima" uniqKey="Albizuri F" first="Fatima" last="Albizuri">Fatima Albizuri</name></author><author><name sortKey="Pascual Salcedo, Dora" sort="Pascual Salcedo, Dora" uniqKey="Pascual Salcedo D" first="Dora" last="Pascual-Salcedo">Dora Pascual-Salcedo</name></author><author><name sortKey="Dreesen, Erwin" sort="Dreesen, Erwin" uniqKey="Dreesen E" first="Erwin" last="Dreesen">Erwin Dreesen</name></author><author><name sortKey="Mulleman, Denis" sort="Mulleman, Denis" uniqKey="Mulleman D" first="Denis" last="Mulleman">Denis Mulleman</name></author></analytic><series><title level="j">Therapeutic drug monitoring</title><idno type="eISSN">1536-3694</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (blood)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (blood)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Biological Products (blood)</term><term>Biological Products (therapeutic use)</term><term>Biopharmaceutics (methods)</term><term>Child</term><term>Drug Monitoring (methods)</term><term>Humans</term><term>Inflammatory Bowel Diseases (blood)</term><term>Inflammatory Bowel Diseases (drug therapy)</term><term>Pediatrics (methods)</term><term>Psoriasis (blood)</term><term>Psoriasis (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (sang)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (sang)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Biopharmacie ()</term><term>Enfant</term><term>Humains</term><term>Maladies inflammatoires intestinales (sang)</term><term>Maladies inflammatoires intestinales (traitement médicamenteux)</term><term>Polyarthrite rhumatoïde (sang)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Produits biologiques (sang)</term><term>Produits biologiques (usage thérapeutique)</term><term>Psoriasis (sang)</term><term>Psoriasis (traitement médicamenteux)</term><term>Pédiatrie ()</term><term>Surveillance pharmacologique ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Inflammatory Bowel Diseases</term><term>Psoriasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Inflammatory Bowel Diseases</term><term>Psoriasis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biopharmaceutics</term><term>Drug Monitoring</term><term>Pediatrics</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Maladies inflammatoires intestinales</term><term>Polyarthrite rhumatoïde</term><term>Produits biologiques</term><term>Psoriasis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies inflammatoires intestinales</term><term>Polyarthrite rhumatoïde</term><term>Psoriasis</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biopharmacie</term><term>Enfant</term><term>Humains</term><term>Pédiatrie</term><term>Surveillance pharmacologique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Biopharmaceuticals have recently emerged as effective treatments for refractory pediatric autoimmune conditions. Several reports have shown a relationship between drug concentration, antidrug antibodies, and clinical response in these patients, strongly suggesting the potential interest, usefulness, and reliability of therapeutic drug monitoring (TDM) in children. This article reviews the current state of research in juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric psoriasis from a TDM point of view. There is a remarkable lack of evidence-based data in pediatric patients, which is reflected throughout the article. Most investigations of TDM are focused on research of tumor necrosis factor alpha antagonists in inflammatory bowel disease, albeit preliminary publications are emerging from pediatric rheumatologists and dermatologists. To date, immunogenicity has been a primary concern, particularly regarding infliximab and adalimumab therapy in children, as it may lead to a loss of therapeutic response. Preliminary investigations show that adjusting the dose according to blood drug concentrations improves disease outcomes by overcoming antidrug antibodies, suggesting a crucial role for TDM. Patients who receive other drugs, such as etanercept, abatacept, or tocilizumab, could benefit from TDM because dosage can be optimized by adjusting it to the minimum effective dose.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Centre-Val de Loire</li><li>Région Centre</li></region><settlement><li>Tours</li></settlement></list><tree><noCountry><name sortKey="Albizuri, Fatima" sort="Albizuri, Fatima" uniqKey="Albizuri F" first="Fatima" last="Albizuri">Fatima Albizuri</name><name sortKey="Dreesen, Erwin" sort="Dreesen, Erwin" uniqKey="Dreesen E" first="Erwin" last="Dreesen">Erwin Dreesen</name><name sortKey="Magallares, Lorena" sort="Magallares, Lorena" uniqKey="Magallares L" first="Lorena" last="Magallares">Lorena Magallares</name><name sortKey="Mulleman, Denis" sort="Mulleman, Denis" uniqKey="Mulleman D" first="Denis" last="Mulleman">Denis Mulleman</name><name sortKey="Pascual Salcedo, Dora" sort="Pascual Salcedo, Dora" uniqKey="Pascual Salcedo D" first="Dora" last="Pascual-Salcedo">Dora Pascual-Salcedo</name></noCountry><country name="France"><region name="Centre-Val de Loire"><name sortKey="Murias, Sara" sort="Murias, Sara" uniqKey="Murias S" first="Sara" last="Murias">Sara Murias</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:28703718
|texte= Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:28703718" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |